Jasper Therapeutics, INC Schedule 13G passive stakes

Millennium Management and affiliated entities have jointly filed a Schedule 13G, reporting beneficial ownership of Jasper Therapeutics, Inc. common stock.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed a Schedule 13G indicating their beneficial ownership of Jasper Therapeutics, Inc. common stock.

Soleus Capital and affiliated entities have filed a Schedule 13G reporting a combined 1% beneficial ownership stake in Jasper Therapeutics, Inc.

The Goldman Sachs Group, Inc. has filed a Schedule 13G reporting a 0.5% beneficial ownership stake in Jasper Therapeutics, Inc.

Millennium Management and affiliated entities have reported a 5.8% beneficial ownership stake in Jasper Therapeutics, Inc. common stock.

Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC have reported a 6.3% beneficial ownership stake in Jasper Therapeutics Inc. common stock.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have reported beneficial ownership of 7.0% of Jasper Therapeutics, Inc.'s voting common stock as of December 31, 2025.

Acorn Bioventures and related entities, managed by Anders Hove, have reported a combined beneficial ownership of 5.3% in Jasper Therapeutics, Inc. common stock.

Acorn Bioventures and related entities, including Anders Hove, have disclosed beneficial ownership of 6.4% of Jasper Therapeutics, Inc.'s common stock.

Qiming U.S. Healthcare Fund II and its affiliates reported a reduced beneficial ownership of 3.3% in Jasper Therapeutics, Inc. as of September 30, 2025.

T. Rowe Price Investment Management, Inc. has reported a 7.1% beneficial ownership stake in Jasper Therapeutics Inc. common stock.

Kingdon Capital Management and Mark Kingdon have filed an amended Schedule 13G, reporting a 4.7% beneficial ownership in Jasper Therapeutics, Inc.

Morgan Stanley has reported reducing its beneficial ownership in Jasper Therapeutics, Inc. to 2.8% of the voting common stock.

Morgan Stanley has disclosed a 5.0% beneficial ownership stake in Jasper Therapeutics, Inc., holding 758,453 shares of Voting Common Stock as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 1.5% beneficial ownership stake in Jasper Therapeutics Inc. as of June 30, 2025.

Kingdon Capital Management, L.L.C. and Mark Kingdon have disclosed a passive beneficial ownership of 5.1% in Jasper Therapeutics, Inc.'s Voting Common Stock.

Soleus Capital Management, L.P. and its affiliated entities, including Soleus Private Equity Fund III, L.P. and Soleus Capital Master Fund, L.P., along with Guy Levy, have reported a combined beneficial ownership of 9.96% of Jasper Therapeutics, Inc.'s common stock as of December 31, 2024, in a passive Schedule 13G/A filing.